Nicotinic acid mononucleotide
Based on 1 publication(s) in Google Scholar
Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD+ biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD+ levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD+ levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease.
For research use only. We do not sell to patients.
- Purity: 98.08%
- CAS No.: 321-02-8
- Formula: C11H14NO9P
- Molecular Weight:335.20
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Glutamine Metabolism Compound Library
HY-L064
-
Gut Microbial Metabolite Library
HY-L078
-
Microbial Metabolite Library
HY-L084
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Food-Sourced Compound Library
HY-L094
-
Anti-Cancer Natural Product Library
HY-L107
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Nicotinic acid mononucleotide
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Nicotinic acid mononucleotide (0-250 μM; assay duration) inhibits the NAD+ hydrolase activity of full-length human SARM1 by binding to its N-terminal ARM domain; its IC50 is 93.3 μM in the absence of NMN, while this inhibitory effect is attenuated in the presence of 5 μM NMN (IC50 = 147.2 μM)[1].
Nicotinic acid mononucleotide delays axonal degeneration of mammalian axons by restoring reduced intracellular NAD+ levels[3].
Nicotinic acid mononucleotide (NAM) increases the expression of Sirt1 and the phosphorylation level of eNOS in human umbilical vein endothelial cells (HUVECs) treated with high glucose[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (8-week-old male; streptozotocin-induced diabetic)[4]
-
Dosage:400 mg/kg/day
-
Administration:i.p.; daily; 8 weeks
-
Result:Partially increased myocardial NAD+ levels in diabetic mice.
Partially reversed impaired left ventricular ejection fraction (LVEF) and fractional shortening (FS) relative to untreated diabetic mice.
Improved myocardial ultrastructural abnormalities (reduced Z-line misalignment, mitochondrial swelling, and myofibril disorganization).
Increased myocardial capillary density relative to untreated diabetic mice.
Reduced myocardial expression of fibrosis markers TGF-β1 and collagen I relative to untreated diabetic mice.
Restored myocardial Sirt1 mRNA and protein expression relative to untreated diabetic mice.
Had no effect on blood glucose or body weight in diabetic mice, and no significant effect on interventricular septal thickness (IVSD) or left ventricular posterior wall thickness (LVPWD).
Chemical Information
-
CAS No. 321-02-8
-
Appearance Solid
-
Molecular Weight 335.20
-
Formula C11H14NO9P
-
Color White to off-white
-
SMILES
O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1[N+]2=CC=CC(C([O-])=O)=C2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Diabetes Res Clin Pract
ACMSD mediated de novo NAD+ biosynthetic impairment in cardiac endothelial cells as a potential therapeutic target for diabetic cardiomyopathy. [Abstract]2023 Dec:206:111014. PMID: 37977551
Solvent & Solubility
H2O : 10 mg/mL (29.83 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sasaki Y, et al. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. Exp Neurol. 2021;345:113842. [Content Brief]
[2]. O'Hara JK, et al. Targeting NAD+ metabolism in the human malaria parasite Plasmodium falciparum. PLoS One. 2014;9(4):e94061. Published 2014 Apr 18. [Content Brief]
[3]. Khan JA, et al. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007;11(5):695-705. [Content Brief]
[4]. Zeng F, et al. ACMSD mediated de novo NAD+ biosynthetic impairment in cardiac endothelial cells as a potential therapeutic target for diabetic cardiomyopathy. Diabetes Res Clin Pract. 2023;206:111014. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.9833 mL | 14.9165 mL | 29.8329 mL | 74.5823 mL |
| 5 mM | 0.5967 mL | 2.9833 mL | 5.9666 mL | 14.9165 mL | |
| 10 mM | 0.2983 mL | 1.4916 mL | 2.9833 mL | 7.4582 mL | |
| 15 mM | 0.1989 mL | 0.9944 mL | 1.9889 mL | 4.9722 mL | |
| 20 mM | 0.1492 mL | 0.7458 mL | 1.4916 mL | 3.7291 mL | |
| 25 mM | 0.1193 mL | 0.5967 mL | 1.1933 mL | 2.9833 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz